# A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain

> **NCT01439100** · PHASE3 · COMPLETED · sponsor: **Mundipharma Research GmbH & Co KG** · enrollment: 172 (estimated)

## Conditions studied

- Parkinson's Disease With Severe Pain

## Interventions

- **DRUG:** Oxycodone/Naloxone Prolonged Release tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01439100
- **Lead sponsor:** Mundipharma Research GmbH & Co KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2013-08
- **Final completion:** 2013-10
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2014-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01439100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01439100, "A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01439100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*